Table 2.
Downregulated circRNAs in OS.
| CircRNA | Sample Types | Targeted Molecules/Axis | Involved Signaling Pathway | Prognostic Relevance | Role in OS Tumorigenesis | Other Tumor Types Tested |
|---|---|---|---|---|---|---|
| circ-LARP4 [203] | MG-63, SaOS-2, patient tissues | miR-424 | - | Low Enneking stage, tumor cell necrosis after adjuvant chemotherapy, prolonged disease-free survival and overall survival | Increasing chemosensitivity to cisplatin and doxorubicin | Gastric cancer [204], hepatocellular carcinoma [205], ovarian cancer [206] |
| hsa_circ0021347 [207] | MG-63, patient tissues | B7-H3 | - | Low tumor stage, low Enneking stage, prolonged survival | - | - |
| hsa_circ_0001258 [208] | MG-63, MG-63/DXR KHOS, KHOS/DXR, U2OS, U2OS/DXR, patient tissues | miR-744-3p/GSTM2 | - | - | Cell viability, increasing chemosensitivity to doxorubicin | - |
| has_circ_0000190 [209] | MG-63, SaOS-2, KHOS, SJSA1, patient tissues, mouse xenograft model | miR-76-5p/TET1 | - | - | Cell proliferation, migration, and invasion inhibition | Gastric cancer [210], plasma cell myeloma [211] |
| circ_0046264 [212] | MG-63, HOS, U2OS, 143B, patient tissues | miR-940/SFRP1 1 | - | Low tumor size and Ki67 proliferation index | Cell proliferation, migration, and invasion inhibition | Lung cancer [213] |
| circ_0001105 [214] | MG-63, U2OS, 143B, patient tissues, mouse xenograft model | miR-766/YTHDF2 | - | Prolonged survival | Cell viability, migration, and invasion inhibition | - |
| circ_32279, circ_24831 [111] | Patient tissues | - | Phosphatidylinositol signaling pathway, inositol phosphate metabolism | - | - | - |
| hsa_circRNA_104980 [181] | MG-63, HOS, U2OS, U2OS/MTX300, ZOS, ZOS-M, 143B, hFOB1.19, patient tissues | hsa-miR-1298-3p, hsa-miR-660-3p | Phosphoric ester hydrolase activity, carbohydrate derivative binding | - | - | - |
| hsa_circ_0000658 [215] | MG-63, SJSA-1, SaOS-2, HOS, U2OS, hFOB1.19, patient tissues, mouse xenograft model | miR-1227/IRF2 2 | - | - | Cell cycle, proliferation, invasion, and migration inhibition | - |
| circMTO1 [216] | MG-63, SaOS-2, HOS, U2OS, hFOB1.19, patient tissues | miR-630/KLF6 | - | Low Enneking stage, prolonged overall survival | Proliferation, migration and invasion inhibition, apoptosis induction | Breast cancer [217], cervical cancer [218], hepatocellular carcinoma [219] |
| circVRK1 [220] | MG-63, SaOS-2, HOS, U2OS, 143B, hFOB1.19, patient tissues, mouse xenograft model | miR-337/ZNF652 3 | - | Low levels correlate to poor prognosis and distant metastasis | Growth, migration, invasion inhibition | Breast cancer [221], esophageal cancer [222] |
| circ_WWC3 [223] | MG-63, SaOS-2, HOS, U2OS, hFOB1.19, patient tissues, mouse xenograft model | miR-421/PDE7B 4 | - | - | Cell growth, migration, invasion inhibition, apoptosis induction | - |
1 Secreted Frizzled Related Protein 1; 2 Interferon Regulatory Factor 2; 3 Zinc-Finger Protein 652; 4 Phosphodiesterase 7B.